Literature DB >> 21521865

Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.

Lea S Eiland1, Thomas M English, Edward H Eiland.   

Abstract

BACKGROUND: Because of concerns regarding increasing microbial resistance to vancomycin, adult treatment guidelines recommend higher trough concentrations based on the type of infectious process. Although these recommendations are not specific to pediatrics, the principles can be extrapolated. Desired higher trough serum concentrations will require escalated dosages of vancomycin in children.
OBJECTIVE: To evaluate current dosing regimens and subsequent trough serum concentrations of vancomycin in children, compare these to reference recommended dosages and guidelines, and predict a dosing equation to achieve desired serum concentrations.
METHODS: Pharmacokinetic parameters of children in a community teaching hospital who were prescribed vancomycin from January 2005 to May 2010 were evaluated in this retrospective chart review. Vancomycin dosing and subsequent serum concentrations were analyzed. Therapeutic serum concentrations were evaluated and compared to vancomycin prescribing and monitoring guidelines by year.
RESULTS: Four hundred thirty-five trough serum concentrations determined in 295 patients were analyzed. The average dosages, when evaluated by year, were 48 mg/kg/day (2005-2008) and 59 mg/kg/day (2009-2010). Using trough concentration recommendations of 5-15 mg/L, vancomycin regimens provided therapeutic trough concentrations 78% of the time from 2005 to 2008. Using 10-20 mg/L as the trough recommendations in 2009-2010, only 49% of serum concentrations reached a therapeutic level. Based on our predictive equation for children aged 1 month-18 years with normal renal function, a vancomycin dosage of 70 mg/kg/day is required to provide trough serum concentrations of 10 mg/L; a dosage of 85 mg/kg/day is required to provide trough serum concentrations of 15 mg/L.
CONCLUSIONS: Our institution was primarily using vancomycin dosing regimens that were recommended in pediatric references (40-60 mg/kg/day), which resulted in subtherapeutic serum concentrations in our population based on new monitoring recommendations. Considering that the currently desired therapeutic trough concentrations of vancomycin are 10-20 mg/L, the total daily dosage should be increased.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521865     DOI: 10.1345/aph.1P588

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  29 in total

Review 1.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Authors:  Geisa Cristina da Silva Alves; Samuel Dutra da Silva; Virginia Paula Frade; Danielle Rodrigues; André de Oliveira Baldoni; Whocely Victor de Castro; Cristina Sanches
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

2.  Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Authors:  Karisma Patel; Ashley S Crumby; Holly D Maples
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

3.  Pediatric Assessment of Vancomycin Empiric Dosing (PAVED): a Retrospective Review.

Authors:  Daniel Rainkie; Mary H H Ensom; Roxane Carr
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

4.  Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.

Authors:  Whitney R Buckel; Shahira Ghobrial; Pranita D Tamma; Aaron M Milstone; Yuan Zhao; Alice J Hsu
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

5.  Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population.

Authors:  Omayma A Kishk; Allison B Lardieri; Emily L Heil; Jill A Morgan
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

6.  Anti-infective use in children and pregnancy: current deficiencies and future challenges.

Authors:  Amanda Gwee; Noel Cranswick
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

7.  Use of Individual Pharmacokinetics to Improve Time to Therapeutic Vancomycin Trough in Pediatric Oncology Patients.

Authors:  Calvin L Miller; S Alexander Winans; John J Veillette; Steven C Forland
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

8.  Evaluation of Vancomycin Dosing in Pediatric Cystic Fibrosis Patients.

Authors:  Erin J McDade; Jennifer L Hewlett; Siby P Moonnumakal; Carol J Baker
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr

9.  Improved vancomycin dosing in children using area under the curve exposure.

Authors:  Jennifer Le; John S Bradley; William Murray; Gale L Romanowski; Tu T Tran; Natalie Nguyen; Susan Cho; Stephanie Natale; Ivilynn Bui; Tri M Tran; Edmund V Capparelli
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

10.  The effect of age and weight on vancomycin serum trough concentrations in pediatric patients.

Authors:  Theresa Madigan; Ronald M Sieve; Kevin K Graner; Ritu Banerjee
Journal:  Pharmacotherapy       Date:  2013-07-17       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.